Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

AIM: This study investigated the effects of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban (10 mg), an oral, direct Factor Xa inhibitor. METHOD: This single centre, non-randomized, non-blinded study included subjects with mild (n = 8) or moderate hepa...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Kubitza, Dagmar, Roth, Angelika, Becka, Michael, Alatrach, Abir, Halabi, Atef, Hinrichsen, Holger, Mueck, Wolfgang
Materialtyp: Artigo
Språk:Inglês
Publicerad: Blackwell Science Inc 2013
Ämnen:
Pharmacokinetics
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3703231/
https://ncbi.nlm.nih.gov/pubmed/23294275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12054
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk